Tumor samples from a single patient with melanoma provided researchers with new information about gene expression profiles that could inform immunotherapy treatments in the future.
In this video we discuss 3-year overall survival data from the KEYNOTE-001 trial, which studied the anti–PD-1 antibody pembrolizumab in patients with advanced melanoma.
Details of a first-in-human case report showed that a patient with melanoma was able to achieve a durable complete response with the combination of two types of immunotherapy.
More than one-third of patients with advanced melanoma were still alive 5 years after starting treatment with the anti-PD-1 immunotherapy nivolumab, according to long-term phase I data.
The combination of TriMixDC-MEL and ipilimumab produced durable tumor responses in patients with pretreated advanced melanoma, according to a phase II study.
Today the FDA approved the PD-1 inhibitor nivolumab (Opdivo) as a single-agent frontline treatment for patients with BRAF wild-type advanced melanoma.
The novel immunotherapy combination of epacadostat plus pembrolizumab shows promising clinical activity in advanced melanoma patients.
Early results from an ongoing trial suggest that pembrolizumab has promising activity in untreated melanoma patients with brain metastases.
Nivolumab alone or in combination with ipilimumab are promising treatment options for patients with mucosal melanoma, according to a new study.
The FDA has approved the MEK inhibitor cobimetinib in combination with the BRAF inhibitor vemurafenib for the treatment of advanced metastatic or unresectable BRAF-mutated melanoma.